Pilot Study of the Genius(TM)2 Tympanic Thermometer in Cardiac Patients Requiring Cardiopulmonary Bypass
1 other identifier
observational
33
1 country
1
Brief Summary
Primary study objective is to test the accuracy of the Genius 2 tympanic thermometer and the Exergen TAT-5000(TM) temporal artery thermometer as compared with serial perioperative core temperature measurements obtained in cardiac surgical patients during cardiopulmonary bypass. Study hypothesis: The Genius 2 thermometer will display greater precision and accuracy than the Exergen TAT-5000 thermometer when compared to core body temperature in patients undergoing CABG surgery.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started May 2008
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
May 1, 2008
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 1, 2009
CompletedStudy Completion
Last participant's last visit for all outcomes
June 1, 2009
CompletedFirst Submitted
Initial submission to the registry
December 7, 2009
CompletedFirst Posted
Study publicly available on registry
December 9, 2009
CompletedDecember 9, 2009
December 1, 2009
1.1 years
December 7, 2009
December 7, 2009
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Thermometer accuracy and precision: 1) Temperature obtained by Genius 2 and Exergen compared to core body temperature (accuracy). 2) Agreement among temperatures taken in triplicate at a given time point (precision).
Subjects are followed for temperature collection until 6 hours post admission to the intensive care unit; lab data and patient outcomes are collected until the time of hospital discharge.
Secondary Outcomes (2)
Effect of environmental conditions before, during and after surgery, on body temperature and thermometer performance (ambient temperature, humidity, diaphoresis, warming devices).
Predetermined perioperative time periods up to 6 hours after intensive care unit admission.
Explore possible relationships between temperature management and duration of CABG surgery and the following patient outcomes: mortality, renal failure (new onset), stroke, myocardial infarction, length of hospital stay, length of ICU stay.
Predetermined perioperative time periods until hospital discharge.
Study Arms (1)
Cardiopulmonary bypass surgery
Thirty to fifty cardiac surgery patients undergoing cardiopulmonary bypass will have serial triplicate temperatures taken by both the Genius 2 tympanic thermometer and the Exergen-TAT 5000 temporal artery thermometer at predetermined perioperative time points. These temperature readings will be compared to at least one core temperature (i.e., pulmonary artery).
Eligibility Criteria
Adults greater than/equal to 18 years of age scheduled for a cardiac surgical procedure requiring cardiopulmonary bypass.
You may qualify if:
- Male or female adult subjects greater than/equal to 18 years of age providing signed informed consent
- Febrile or afebrile
- Planned monitoring of core temperature at a minimum of two separate sites, one of which includes the pulmonary artery
- Planned use of cardiopulmonary bypass for a cardiac surgical procedure.
You may not qualify if:
- Mist tents or oxygen hoods
- Hot or cold applications to the head
- Patients that have the planned use of deep hypothermic circulatory arrest
- Aural anomalies (e.g., external auditory canal less than 2cm in length, persistent ear pain)
- Blood, cerumen, excessive hair, inflammation, infection, ulceration or foreign object in the ear observed by otoscopic examination
- Any other signs or symptoms of distress or a condition which would, or in the opinion of the principal investigator, render their participation in the study detrimental to their well-being.
- Previous refusal or enrollment in this study
- Previous or concurrent participation in a clinical trial of a drug or device within the past 30 days.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
Study Officials
- PRINCIPAL INVESTIGATOR
Edwin Avery, MD
Massachusetts General Hospital Corporation
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- INDUSTRY
Study Record Dates
First Submitted
December 7, 2009
First Posted
December 9, 2009
Study Start
May 1, 2008
Primary Completion
June 1, 2009
Study Completion
June 1, 2009
Last Updated
December 9, 2009
Record last verified: 2009-12